Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT04621318
- Locations
- 🇺🇸
Biotrial, Newark, New Jersey, United States
🇫🇷Biotrial Rennes, Rennes, France
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 36
- Registration Number
- NCT04232657
- Locations
- 🇺🇸
James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States
🇺🇸Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
Circulating Myokine Levels and Bone Metabolism
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- 424 General Military Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT04206618
- Locations
- 🇬🇷
424 General Military Hospital, Thessaloniki, Northern Greece, Greece
Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT04087096
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
RANKL Inhibition and Mammographic Breast Density
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 210
- Registration Number
- NCT04067726
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Kwong Wah Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04034199
- Locations
- 🇭🇰
Kwong Wah Hospital, Hong Kong, Hong Kong
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04026256
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Markers of Osteoporosis in Cystic Fibrosis
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT03921060
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Denosumab Sequential Therapy
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 101
- Registration Number
- NCT03868033
- Locations
- 🇨🇳
Department of Orthopedics, National Taiwan University Hospital, Taipei, N/A = Not Applicable, Taiwan
Denosumab for Smoldering Multiple Myeloma
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT03839459
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.